MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

Molecular testing for suspected hereditary transthyretin amyloidosis (hATTR) is covered when patients have a clinical diagnosis of ATTR, cardiac features suggestive of ATTR-cardiomyopathy or progressive sensorimotor/autonomic neuropathy combined with supportive family history or additional guideline-based features, or a known first-degree relative with hATTR. Coverage requires that patients be offered pre-test counseling, results will inform treatment decisions, the test include at least guideline-supported minimum genetic content, single-variant testing be limited to known familial variants, and the test has successfully completed a technical assessment.

"Molecular diagnostic testing is covered when the patient has a clinical diagnosis of ATTR."

Sign up to see full coverage criteria, indications, and limitations.